Published in J Clin Oncol on February 01, 1997
Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures? CMAJ (2003) 1.18
Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis. Oncologist (2014) 0.91
Bevacizumab in ovarian cancer: A critical review of phase III studies. Oncotarget (2016) 0.75
Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med (1997) 19.00
Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med (1999) 10.94
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
What do we mean by partnership in making decisions about treatment? BMJ (1999) 5.31
A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med (1992) 4.60
Controlling health expenditures--the Canadian reality. N Engl J Med (1989) 4.36
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24
System for Health Area Resource Planning (SHARP): an application to Ontario medical school enrollment. CMAJ (1994) 4.11
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med (1993) 3.61
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ (1992) 3.33
Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making (1989) 3.26
Health care contingent valuation studies: a review and classification of the literature. Health Econ (1998) 3.13
The Early External Cephalic Version (ECV) 2 Trial: an international multicentre randomised controlled trial of timing of ECV for breech pregnancies. BJOG (2011) 2.97
Prevention of venous thromboembolism. Chest (1995) 2.69
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Universal precautions to prevent HIV transmission to health care workers: an economic analysis. CMAJ (1990) 2.68
Cost-effectiveness ratios: in a league of their own. Health Policy (1994) 2.55
Needle exchange programs: an economic evaluation of a local experience. CMAJ (1997) 2.46
Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol (1989) 2.22
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. J Clin Oncol (1998) 1.97
Analysis of fluorescence decay curves by means of the Laplace transformation. Biophys J (1975) 1.96
Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol (1996) 1.91
Physician-patient-companion communication and decision-making: a systematic review of triadic medical consultations. Patient Educ Couns (2013) 1.89
Discounting in the economic evaluation of health care interventions. Med Care (1993) 1.89
Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst (1992) 1.87
Comparison of cervical, urethral, and urine specimens for the detection of Chlamydia trachomatis in women. J Infect Dis (1991) 1.87
Prevention of venous thromboembolism. Chest (1992) 1.81
Low molecular weight heparin. Blood (1992) 1.74
The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making (1991) 1.73
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol (1986) 1.73
Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med (2000) 1.71
Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS (1999) 1.70
Physician supply in Ontario: further observations on SHARP and the SHARP projections. CMAJ (1995) 1.67
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med (1986) 1.67
Breast irradiation postlumpectomy: development and evaluation of a decision instrument. J Clin Oncol (1995) 1.66
Shared decision making in a publicly funded health care system. Policies exist to reduce the risk of conflict between individual and society. BMJ (1999) 1.65
A randomized trial on the efficacy of an autologous blood drainage and transfusion device in patients undergoing elective knee arthroplasty. Transfusion (1992) 1.62
Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ (2001) 1.59
How to improve communication between doctors and patients. Learning more about the decision making context is important. BMJ (2000) 1.55
Newborn circumcision: an economic perspective. Can Med Assoc J (1984) 1.54
When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making (1996) 1.53
Is it 'worthwhile' to continue treating patients with a prolonged stay (>14 days) in the ICU? An economic evaluation. Chest (1998) 1.47
Individual correlates of health service utilization and the cost of poor adjustment to chronic illness. Med Care (1990) 1.44
Mastectomy or lumpectomy? Helping women make informed choices. J Clin Oncol (1999) 1.42
Preoperative HIV testing: is it less expensive than universal precautions? J Clin Epidemiol (1993) 1.41
Effectiveness and efficiency of selective vs universal screening for chlamydial infection in sexually active young women. Arch Intern Med (1992) 1.41
The HER-2/neu oncogene in breast cancer: so what is new? J Clin Oncol (1992) 1.39
Understanding economic evaluations: a review of the knee arthroplasty literature. Am J Knee Surg (1999) 1.38
The supportive care needs of newly diagnosed cancer patients attending a regional cancer center. Cancer (1997) 1.35
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med (1997) 1.34
Outcomes and costs of coronary artery bypass grafting: comparison between octogenarians and septuagenarians at a tertiary care centre. CMAJ (2001) 1.33
Epidemiology of thrombosis in cancer. Acta Haematol (2001) 1.33
Chemotherapy waste reduction through shelf-life extension. Can J Hosp Pharm (1994) 1.29
Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet (1987) 1.25
Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ (2002) 1.25
Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress. Med Decis Making (1994) 1.21
Characterising doctor-parent communication in counselling for impending preterm delivery. Arch Dis Child Fetal Neonatal Ed (2002) 1.21
When the bough breaks: provider-initiated comprehensive care is more effective and less expensive for sole-support parents on social assistance. Soc Sci Med (2001) 1.16
Reliability and intraoperative validity of preoperative assessment of standardized plain radiographs in predicting bone loss at revision hip surgery. J Bone Joint Surg Am (2001) 1.15
A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev Respir Dis (1990) 1.13
Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis (1984) 1.13
Fluorescence decay studies of reduced nicotinamide adenine dinucleotide in solution and bound to liver alcohol dehydrogenase. Biochemistry (1976) 1.13
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost (2010) 1.12
Economic evaluations of community-based care: lessons from twelve studies in Ontario. J Eval Clin Pract (1999) 1.12
Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol (1998) 1.12
Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost (1986) 1.10
Hemorrhagic complications of anticoagulant treatment. Chest (1995) 1.10
Age-related changes in the redox status of rat muscle cells and their role in enzyme-aging. Mech Ageing Dev (1985) 1.09
The quality of QALYs (quality-adjusted-life-years): do QALYs measure what they at least intend to measure? Health Policy (1989) 1.08
Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. Ann Intern Med (1987) 1.08
Nanosecond decay studies of a fluorescence probe bound to apomyoglobin. Biophys J (1977) 1.06
Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics (2001) 1.05
Frequency and methodologic rigor of quality-of-life assessments in the critical care literature. Crit Care Med (1998) 1.05
Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference? Pharmacoeconomics (1999) 1.05
Problem-solving counseling for caregivers of the cognitively impaired: effective for whom? Nurs Res (1999) 1.04
Evaluation of public investment in health care. Is the risk irrelevant? J Health Econ (1983) 1.04
Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit Care Med (1996) 1.03
Aggregation of an amyloidogenic fragment of human islet amyloid polypeptide. Biochim Biophys Acta (2000) 1.02
Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med (1993) 1.02
The Control of Hypertension In Pregnancy Study pilot trial. BJOG (2007) 1.02
Long-lived tryptophan fluorescence in phosphoglycerate mutase. Biochemistry (1989) 1.01
The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost (1999) 1.01
Are health states "timeless"? The case of the standard gamble method. J Clin Epidemiol (1999) 1.01
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest (1992) 1.01
Women's perceptions about treatment decision making for ovarian cancer. Gynecol Oncol (2003) 1.00
A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med (1992) 1.00
Developing a model of collaborative research: the complexities and challenges of implementation. Int J Nurs Stud (2000) 0.98
Time-resolved circularly polarized protein phosphorescence. Proc Natl Acad Sci U S A (1992) 0.98
Prospective care of elderly patients in family practice. Is screening effective? Can Fam Physician (1998) 0.98
Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism. Contemp Clin Trials (2011) 0.98
Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost (1989) 0.97